Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients

BACKGROUND. Cell-free circulating nucleic acids, including 22-nt microRNAs (miRNAs), represent noninvasive biomarkers for treatment response monitoring of cancer patients. While the majority of plasma miRNA is bound to proteins, a smaller, less well-characterized pool is associated with extracellular vesicles (EVs). Here, we addressed whether EV-associated miRNAs reflect metabolic disease in classical Hodgkin lymphoma (cHL) patients. METHODS. With standardized size-exclusion chromatography (SEC), we isolated EV-associated extracellular RNA (exRNA) fractions and protein-bound miRNA from plasma of cHL patients and healthy subjects. We performed a comprehensive small RNA sequencing analysis and validation by TaqMan qRT-PCR for candidate discovery. Fluorodeoxyglucose-PET (FDG-PET) status before treatment, directly after treatment, and during long-term follow-up was compared directly with EV miRNA levels. RESULTS. The plasma EV miRNA repertoire was more extensive compared with protein-bound miRNA that was heavily dominated by a few abundant miRNA species and was less informative of disease status. Purified EV fractions of untreated cHL patients and tumor EVs had enriched levels of miR24-3p, miR127-3p, miR21-5p, miR155-5p, and let7a-5p compared with EV fractions from healthy subjects and disease controls. Serial monitoring of EV miRNA levels in patients before treatment, directly after treatment, and during long-term follow-up revealed robust, stable decreases in miRNA levels matching a complete metabolic response, as observed with FDG-PET. Importantly, EV miRNA levels rose again in relapse patients. CONCLUSION. We conclude that cHL-related miRNA levels in circulating EVs reflect the presence of vital tumor tissue and are suitable for therapy response and relapse monitoring in individual cHL patients. FUNDING. Cancer Center Amsterdam Foundation (CCA-2013), Dutch Cancer Society (KWF-5510), Technology Foundation STW (STW Perspectief CANCER-ID).

[1]  R. Küppers,et al.  Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[2]  Mark Gerstein,et al.  Diverse human extracellular RNAs are widely detected in human plasma , 2016, Nature Communications.

[3]  J. Carpten,et al.  Translating RNA sequencing into clinical diagnostics: opportunities and challenges , 2016, Nature Reviews Genetics.

[4]  T. Wurdinger,et al.  Sensing of latent EBV infection through exosomal transfer of 5′pppRNA , 2016, Proceedings of the National Academy of Sciences.

[5]  L. Larocca,et al.  CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma , 2016, Cancer medicine.

[6]  E. Vigorito,et al.  MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis. , 2016, The Journal of clinical investigation.

[7]  Pieter Wesseling,et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics , 2015, Cancer cell.

[8]  Jun Yao,et al.  Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth , 2015, Nature.

[9]  Ash A. Alizadeh,et al.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. , 2015, Blood.

[10]  Joanne L Welton,et al.  Ready-made chromatography columns for extracellular vesicle isolation from plasma , 2015, Journal of extracellular vesicles.

[11]  H. D. del Portillo,et al.  Size-exclusion chromatography-based enrichment of extracellular vesicles from urine samples , 2015, Journal of extracellular vesicles.

[12]  A. Möller,et al.  Optimized exosome isolation protocol for cell culture supernatant and human plasma , 2015, Journal of extracellular vesicles.

[13]  Ángel M. Alganza,et al.  sRNAbench: profiling of small RNAs and its sequence variants in single or multi-species high-throughput experiments , 2014 .

[14]  Muneesh Tewari,et al.  Quantitative and stoichiometric analysis of the microRNA content of exosomes , 2014, Proceedings of the National Academy of Sciences.

[15]  B. Ylstra,et al.  Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. , 2014, Cell reports.

[16]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Victor R. Ambros,et al.  Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis , 2014, Proceedings of the National Academy of Sciences.

[18]  V. Ambros,et al.  An efficient and sensitive method for preparing cDNA libraries from scarce biological samples , 2014, Nucleic acids research.

[19]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[21]  R. Nieuwland,et al.  Single-step isolation of extracellular vesicles by size-exclusion chromatography , 2014, Journal of extracellular vesicles.

[22]  Atul Bhatnagar,et al.  Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2013, Clinical Cancer Research.

[23]  R. Biondi,et al.  Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers , 2013, PloS one.

[24]  Thomas Tuschl,et al.  Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations , 2013, Proceedings of the National Academy of Sciences.

[25]  M. Gandhi,et al.  Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2012, Clinical Cancer Research.

[26]  Willem Stoorvogel,et al.  Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry , 2012, Nature Protocols.

[27]  R. Greil,et al.  Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Pruim,et al.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma , 2012, Haematologica.

[29]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[30]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[31]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[32]  Bruce D Cheson,et al.  Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[34]  Dereje D. Jima,et al.  Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. , 2010, Blood.

[35]  D Michiel Pegtel,et al.  Exosomes: Fit to deliver small RNA. , 2010, Communicative & integrative biology.

[36]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[37]  L. Leoncini,et al.  B‐cell differentiation in EBV‐positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA‐altered expression , 2010, International journal of cancer.

[38]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[39]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[40]  R. Boellaard,et al.  Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments , 2009, Leukemia & lymphoma.

[41]  D. Jong,et al.  Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma , 2009, Modern Pathology.

[42]  Peter Möller,et al.  Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. , 2009, Neoplasia.

[43]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[44]  T. Tuschl,et al.  Tumorigenesis and Neoplastic Progression MicroRNA-Mediated Down-Regulation of PRDM 1 / Blimp-1 in Hodgkin / Reed-Sternberg Cells : A Potential Pathogenetic Lesion in Hodgkin Lymphomas , 2010 .

[45]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[46]  A. van den Berg,et al.  BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas , 2005, The Journal of pathology.

[47]  A. van den Berg,et al.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. , 1999, The American journal of pathology.

[48]  Kenneth W Witwer,et al.  Circulating microRNA biomarker studies: pitfalls and potential solutions. , 2015, Clinical chemistry.

[49]  F. Verweij,et al.  Analysis of viral microRNA exchange via exosomes in vitro and in vivo. , 2013, Methods in molecular biology.

[50]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.